The BLA seeking accelerated approval for patritumab deruxtecan in previously treated, locally advanced EGFR-mutated NSCLC in ...

A phase II study of atezolizumab combined with cisplatin and vinorelbine as adjuvant therapy for completely resected non-small cell lung cancer with EGFR mutation (WJOG11719L: ADJUST study).

Patritumab deruxtecan was unable to significantly improve overall survival in patients with locally advanced or metastatic ...

Summit Therapeutics' recent stock sell-off reflects regulatory uncertainty rather than drug failure. Click here to read an ...

Helena Yu, MD, discusses the efficacy of zipalertinib for EGFR-mutant non–small cell lung cancer and the importance of exploring therapies with CNS penetration in this space.

Among the lung cancer population with EGFR mutations, patients with insertions at exon 20 (ex20ins) represent a significant unmet need segment. These patients often have poorer outcomes compared to ...

In its first global phase 3 readout, Akeso and Summit Therapeutics’ closely watched PD-1xVEGF bispecific antibody ivonescimab ...

Hutchmed China reported positive interim results from its phase three ‘SACHI’ trial on Monday, showing that the combination ...

Findings from HERTHENA-Lung02 showed that the key secondary endpoint of overall survival did not meet statistical significance.

Ivonescimab helped cut the risk of lung tumor progression in half in a multi-country Phase 3 trial. But it hasn’t yet clearly ...

Rahway: Daiichi Sankyo and Merck, known as MSD outside of the United States and Canada, have announced that the Biologics ...

Summit Therapeutics (NASDAQ:SMMT) announced on Friday that its lead asset, ivonescimab, developed with its Chinese partner ...